Starpharma Holdings Ltd. (OTCMKTS:SPHRY – Get Free Report) was the target of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 101 shares, an increase of ∞ from the July 30th total of 0 shares. Based on an average trading volume of 796 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are sold short.
Starpharma Stock Performance
Shares of SPHRY stock opened at $5.30 on Tuesday. Starpharma has a fifty-two week low of $0.73 and a fifty-two week high of $5.70. The stock has a 50 day moving average price of $4.90 and a two-hundred day moving average price of $4.40.
About Starpharma
Starpharma is a clinical-stage biopharmaceutical company specializing in the development of dendrimer-based products across infectious disease, oncology and ophthalmology. Its proprietary dendrimer platform, DEP™ (Dendrimer Enhanced Products), enables precise molecular engineering to enhance drug delivery, targeting and safety profiles. The company’s lead product, VivaGel®, is a topical microbicide that has been approved in multiple markets for the treatment and prevention of bacterial vaginosis and is in clinical development for antiviral applications.
In addition to VivaGel, Starpharma is advancing pipeline candidates that leverage DEP technology to improve the performance of established and novel therapeutic agents.
See Also
- Five stocks we like better than Starpharma
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.
